Ann: Medibio Quarterly Update and Cashflow Report, page-5

700k on an investigation for the former CEO that resulted in no charges and no outcome that was worth reporting to the market? If that is not Board misconduct I'm not sure what is.

CE and TGA approvals are unrelated to the FDA application and were not blinded studies which the marketing team presumably have written here.  Good that they've had no FDA delay cited to them yet. They usually would have found out by now if you look at FDA timeline protocols. 

Cash position gives them less than 60 days if you consider other commitments.  I don't know what the definition of trading insolvent is but it must be close.  It will be tough getting a quality CEO to sign on when there is no ability to pay them beyond a few months.  

Anyone have any thoughts on whether it will be FDA, a big contract or funding through the Board changes if the Khouri group come through that saves us?